Selective Androgen Receptor Modulators (SARMs) are a class of therapeutic compounds that have similar properties to anabolic agents, but with reduced androgenic properties. This property allows SARMs the advantage of androgen-receptor specificity, tissue selectivity, and the lack of steroid-related side effects.
SARMs have the ability to differentiate between anabolic and androgenic activities, and this provides the potential for therapeutic opportunities in a variety of medical conditions including muscle-wasting diseases, osteoporosis, and hypogonadism.
Taking the male viewpoint, when talking SARMs, if the target is bone growth in in an older man that suffers from osteopenia or osteoporosis, but with no overt signs of hypogonadism, a SARM targeting the bone and muscle tissue, but with less activity on the prostate or testes, would be more suitable.
And for women, SARMs would ideally stimulate bone retention, or libido and other function that androgens can influence, ut without the negative side-effects found in anabolics, such as development of male gender characteristics.